INT172570

From wiki-pain
Revision as of 04:16, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 6.27
Pain Relevance 1.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

SCLC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
qutenza 130 99.98 Very High Very High Very High
cytokine 4 98.68 Very High Very High Very High
aspirin 50 83.68 Quite High
palliative 2 72.44 Quite High
Inflammation 5 72.24 Quite High
cINOD 14 61.56 Quite High
vincristine 40 5.00 Very Low Very Low Very Low
Neuropeptide 4 5.00 Very Low Very Low Very Low
Analgesic 3 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Small Cell Lung Cancer 226 100.00 Very High Very High Very High
Non-small-cell Lung Cancer 33 100.00 Very High Very High Very High
Disease 59 98.80 Very High Very High Very High
Cancer 87 98.36 Very High Very High Very High
Lung Cancer 88 95.76 Very High Very High Very High
Neutropenia 24 95.56 Very High Very High Very High
Recurrence 4 93.48 High High
Apoptosis 12 90.92 High High
Metastasis 12 88.96 High High
Reprotox - General 1 4 87.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
has been shown to upregulate E-cadherin in NSCLC, there are no
Positive_regulation (upregulate) of SCLC associated with non-small-cell lung cancer
1) Confidence 0.67 Published 2008 Journal PPAR Research Section Body Doc Link PMC2396386 Disease Relevance 0.61 Pain Relevance 0.05
Although several agents are active against SCLC and initial response rates to standard first-line therapies are as high as 90% in patients with limited-stage disease, most patients with SCLC experience disease relapse (Okuno and Jett 2002).
Positive_regulation (active) of SCLC associated with disease, small cell lung cancer and recurrence
2) Confidence 0.30 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387299 Disease Relevance 2.05 Pain Relevance 0.07
Although topotecan combination therapies appear to be active in recurrent SCLC, response rates are similar to those reported in response to topotecan monotherapy.
Positive_regulation (active) of SCLC associated with small cell lung cancer
3) Confidence 0.28 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387299 Disease Relevance 1.13 Pain Relevance 0
While COX-2 expression was generally shown to be increased in NSCLC and to a much lesser extent in SCLC, the role of COX-2 expression in latter tumor type is difficult to determine, due to the fact that the numbers of SCLC tumors examined in these studies was very small.
Positive_regulation (increased) of SCLC associated with cancer, non-small-cell lung cancer and small cell lung cancer
4) Confidence 0.20 Published 2002 Journal BMC Cancer Section Body Doc Link PMC138809 Disease Relevance 1.19 Pain Relevance 0.31
Our results showed for the first time that capsaicin induces G1 arrest in four human SCLC cell lines in a concentration dependent manner.
Positive_regulation (induces) of SCLC associated with qutenza and small cell lung cancer
5) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 1.29 Pain Relevance 1.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox